@entity259 represent a broad spectrum of @entity5 with different biologic behaviors. The majority of these @entity5 can be readily diagnosed by characteristic histopathologic features, but the distinction between @entity652 and @entity189 can be difficult. Recent studies with cell cycle proteins such as @entity13525 ( @entity13525 ), a cell cycle inhibitory protein, and Ki-67, a proliferation marker, suggest that these markers might be useful in predicting the behavior of various @entity5 . We analyzed 95 @entity1374 (16 @entity652 , 23 @entity189 , 22 @entity1377 , 27 @entity189 , plus 7 non-neoplastic thyroids [NNTs], used as a control group) for expression of @entity13525 and Ki-67 by immunostaining. The distribution of immunoreactivity was analyzed by quantifying nuclear staining in each case without knowledge of the diagnosis or outcome. Clinical history and follow-up information were obtained by chart review. There were significant differences in the expression of @entity13525 between @entity652 ( @entity894 [ @entity894 ] = 47.9+/-5.6) and @entity189 ( @entity894 = 15.7+/-2.0). @entity1377 ( @entity894 = 11.6+/-3.0) and @entity189 ( @entity894 = 9.4+/-1.7) had @entity13525 LIs similar to that of @entity189 ; the NNT group had the highest @entity13525 @entity894 (74.1+/-4.9). The Ki-67 @entity189 (57.6+/-3.8) was more than threefold greater than that of any other group. Logistic regression showed that @entity13525 was effective in distinguishing @entity652 from @entity189 (P = .0056) and that Ki-67 could also distinguish @entity652 from @entity189 (P = .0060). @entity189 with and without @entity3 showed significantly higher expression of Ki-67 in @entity1 with @entity3 (P = .0019). These results indicate that antibodies to @entity13525 and Ki-67 might be useful in distinguishing between @entity259 that are difficult to diagnose by the usual histopathologic criteria.

Expression of @entity13525 and Ki-67 in benign and malignant XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinomas', 'Papillary carcinomas'] @entity894 :: ('MESH:C566784', 'Disease') :: ['labeling index', 'LI'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasms', 'tumors'] @entity189 :: ('MESH:D002277', 'Disease') :: ['anaplastic carcinomas', 'follicular carcinomas', 'LI of anaplastic carcinomas', 'Analysis of follicular carcinomas'] @entity13525 :: ('1027', 'Gene') :: ['p27', 'p27kip1'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity652 :: ('MESH:D000236', 'Disease') :: ['follicular adenomas'] @entity259 :: ('MESH:D013964', 'Disease') :: ['Thyroid neoplasms', 'thyroid neoplasms'] @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroid lesions']
@entity259 :: (MESH:D013964,Disease) :: ['thyroid tumors']
